Primary Malignant Melanoma of the Urethra: A Rare Finding.

Primary urinary tract metastatic melanoma is an extremely rare cancer involving the urinary tract. In the majority of melanomas, skin melanocytes can become damaged by ultraviolet radiation and cause melanoma. However, in rare cases, melanocytes in mucosal tissue can develop into melanoma, which can be challenging to diagnose and treat. This case report describes managing and treating a patient with an extremely rare primary cancer finding. We describe the case of a patient who was diagnosed with primary metastatic melanoma of the urinary tract following an extensive and detailed diagnostic period of 2.5 months. After review by an interdisciplinary tumor board and a shared decision-making process with the patient, he agreed to immunotherapy with ipilimumab and nivolumab. The patient survived nearly five months after the initiation of treatment. The cause of death was challenging to determine due to it being unwitnessed; however, it is suspected to be cardiovascular-related, owing to a history of severe cardiovascular disease and an acute stress event prior to death.

Hepatocellular Carcinoma With Tumor Thrombus Extension Into the Right Atrium of the Heart.

Hepatocellular carcinoma (HCC) is the most common primary liver tumor. Most patients present to the hospital with systemic symptoms and typically have a history of liver disease. This case study involves a male in his 60s who presented to our hospital facility with a chief complaint of abdominal pain. He reported no history of liver disease but was diagnosed with HCC stage IVB during this hospitalization. Upon further imaging, a tumor thrombus was found invading the inferior vena cava with an extension into the right atrium. Our primary learning point in this article is to emphasize the importance of prompt surveillance for primary care physicians with patients who are at increased risk for HCC. Additionally, we discuss specific management aimed toward patients diagnosed with a tumor thrombus extending into the right atrium. This management includes dual immunotherapy (atezolizumab and bevacizumab) and transarterial chemotherapy embolization (TACE).

Thyrotoxic Periodic Paralysis With Hypokalemia: A Case Study.

Thyrotoxic periodic paralysis (TPP) is a rare life-threatening condition most commonly seen in individuals between the ages of 20-40 years. It is most prevalent in Hispanic and Asian populations. Here we present a case report of a young male patient admitted to our facility with an acute onset of paralysis. He was found to have new-onset hyperthyroidism and severe hypokalemia. TPP was exacerbated by the intake of a high-carbohydrate meal as well as a steroid injection within 24 hours of symptom onset.